KR20120007059A - 4―(3―클로로―2―플루오로―아닐리노)―7―메톡시―6―[[1―(n―메틸카르바모일메틸)―피페리딘―4―일]옥시]퀴나졸린의 제조 방법 - Google Patents
4―(3―클로로―2―플루오로―아닐리노)―7―메톡시―6―[[1―(n―메틸카르바모일메틸)―피페리딘―4―일]옥시]퀴나졸린의 제조 방법 Download PDFInfo
- Publication number
- KR20120007059A KR20120007059A KR1020117027878A KR20117027878A KR20120007059A KR 20120007059 A KR20120007059 A KR 20120007059A KR 1020117027878 A KR1020117027878 A KR 1020117027878A KR 20117027878 A KR20117027878 A KR 20117027878A KR 20120007059 A KR20120007059 A KR 20120007059A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- chloro
- acid
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 C*(C)(C)C(CCN)=O Chemical compound C*(C)(C)C(CCN)=O 0.000 description 2
- OMMXWGVWKMGOOU-LPYMAVHISA-N CNC(CN(CC1)CCC1Oc(c(OC)c1)cc(C#N)c1/N=C/N(C)C)=O Chemical compound CNC(CN(CC1)CCC1Oc(c(OC)c1)cc(C#N)c1/N=C/N(C)C)=O OMMXWGVWKMGOOU-LPYMAVHISA-N 0.000 description 2
- OLLZXQIFCRIRMH-UHFFFAOYSA-N CCCC(NC)=O Chemical compound CCCC(NC)=O OLLZXQIFCRIRMH-UHFFFAOYSA-N 0.000 description 1
- AQQHAIRDIPXYKA-UHFFFAOYSA-N CNC(CN(CC1)CCC1Oc(cc(c(N)c1)C#N)c1OC)=O Chemical compound CNC(CN(CC1)CCC1Oc(cc(c(N)c1)C#N)c1OC)=O AQQHAIRDIPXYKA-UHFFFAOYSA-N 0.000 description 1
- BKVWGWVOQLLRJO-UHFFFAOYSA-N CNC(CN(CC1)CCC1Oc(cc(c([N+]([O-])=O)c1)C#N)c1OC)=O Chemical compound CNC(CN(CC1)CCC1Oc(cc(c([N+]([O-])=O)c1)C#N)c1OC)=O BKVWGWVOQLLRJO-UHFFFAOYSA-N 0.000 description 1
- LXHXCGWQLBRXMU-UHFFFAOYSA-N CNC(CN(CC1)CCC1Oc(cc(cc1)C#N)c1OC)=O Chemical compound CNC(CN(CC1)CCC1Oc(cc(cc1)C#N)c1OC)=O LXHXCGWQLBRXMU-UHFFFAOYSA-N 0.000 description 1
- DNIAOKUSLZWYIJ-UHFFFAOYSA-N COc(ccc(C#N)c1)c1OC1CCNCC1 Chemical compound COc(ccc(C#N)c1)c1OC1CCNCC1 DNIAOKUSLZWYIJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17199409P | 2009-04-23 | 2009-04-23 | |
| US61/171,994 | 2009-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20120007059A true KR20120007059A (ko) | 2012-01-19 |
Family
ID=42224659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117027878A Withdrawn KR20120007059A (ko) | 2009-04-23 | 2010-04-22 | 4―(3―클로로―2―플루오로―아닐리노)―7―메톡시―6―[[1―(n―메틸카르바모일메틸)―피페리딘―4―일]옥시]퀴나졸린의 제조 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8450482B2 (enExample) |
| EP (1) | EP2421827A2 (enExample) |
| JP (1) | JP2012524769A (enExample) |
| KR (1) | KR20120007059A (enExample) |
| CN (1) | CN102459174A (enExample) |
| AR (1) | AR076407A1 (enExample) |
| AU (1) | AU2010240717A1 (enExample) |
| BR (1) | BRPI1013854A2 (enExample) |
| CA (1) | CA2758610A1 (enExample) |
| IL (1) | IL215388A0 (enExample) |
| MX (1) | MX2011011177A (enExample) |
| SG (1) | SG174893A1 (enExample) |
| TW (1) | TW201041871A (enExample) |
| WO (1) | WO2010122340A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101272613B1 (ko) | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 |
| CN108503596A (zh) * | 2018-03-14 | 2018-09-07 | 盐城师范学院 | 一种新的厄洛替尼及其中间体的制备方法 |
| CN108440420A (zh) * | 2018-03-22 | 2018-08-24 | 盐城师范学院 | 酪氨酸激酶抑制剂拉帕替尼及其关键中间体的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324597B (en) | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0320793D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Chemical process |
| JP4036885B2 (ja) | 2003-09-19 | 2008-01-23 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| US20070299092A1 (en) * | 2004-05-20 | 2007-12-27 | Wyeth | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors |
| WO2009138779A1 (en) * | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline |
| BRPI0912170A2 (pt) * | 2008-05-13 | 2015-10-13 | Astrazeneca Ab | composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente |
-
2010
- 2010-04-22 US US13/264,217 patent/US8450482B2/en not_active Expired - Fee Related
- 2010-04-22 KR KR1020117027878A patent/KR20120007059A/ko not_active Withdrawn
- 2010-04-22 MX MX2011011177A patent/MX2011011177A/es not_active Application Discontinuation
- 2010-04-22 BR BRPI1013854A patent/BRPI1013854A2/pt not_active IP Right Cessation
- 2010-04-22 SG SG2011068426A patent/SG174893A1/en unknown
- 2010-04-22 CN CN2010800288080A patent/CN102459174A/zh active Pending
- 2010-04-22 JP JP2012506579A patent/JP2012524769A/ja active Pending
- 2010-04-22 CA CA2758610A patent/CA2758610A1/en not_active Abandoned
- 2010-04-22 WO PCT/GB2010/050653 patent/WO2010122340A2/en not_active Ceased
- 2010-04-22 EP EP10715333A patent/EP2421827A2/en not_active Withdrawn
- 2010-04-22 AU AU2010240717A patent/AU2010240717A1/en not_active Abandoned
- 2010-04-23 TW TW099112893A patent/TW201041871A/zh unknown
- 2010-04-23 AR ARP100101374A patent/AR076407A1/es not_active Application Discontinuation
-
2011
- 2011-09-26 IL IL215388A patent/IL215388A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010122340A8 (en) | 2011-12-15 |
| SG174893A1 (en) | 2011-11-28 |
| EP2421827A2 (en) | 2012-02-29 |
| AU2010240717A1 (en) | 2011-10-27 |
| JP2012524769A (ja) | 2012-10-18 |
| AR076407A1 (es) | 2011-06-08 |
| MX2011011177A (es) | 2011-11-18 |
| TW201041871A (en) | 2010-12-01 |
| IL215388A0 (en) | 2011-12-29 |
| WO2010122340A3 (en) | 2011-09-09 |
| CN102459174A (zh) | 2012-05-16 |
| US20120108814A1 (en) | 2012-05-03 |
| US8450482B2 (en) | 2013-05-28 |
| BRPI1013854A2 (pt) | 2017-05-16 |
| CA2758610A1 (en) | 2010-10-28 |
| WO2010122340A2 (en) | 2010-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6889494B2 (ja) | ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法 | |
| JP6437820B2 (ja) | キナゾリン誘導体、その製造方法、中間体、組成物及びその適用 | |
| JP6704422B2 (ja) | キナゾリン誘導体の塩およびその製造方法 | |
| TWI443095B (zh) | 新穎鹽 | |
| KR101378260B1 (ko) | 세로토닌 및 노르에피네프린 재흡수 억제제 | |
| KR20120007059A (ko) | 4―(3―클로로―2―플루오로―아닐리노)―7―메톡시―6―[[1―(n―메틸카르바모일메틸)―피페리딘―4―일]옥시]퀴나졸린의 제조 방법 | |
| KR20010042471A (ko) | Mrp1의 억제 방법 | |
| JP4783738B2 (ja) | 置換ジヒドロキナゾリンii | |
| US10150739B2 (en) | Crystalline form of androgen receptor inhibitor and preparation method thereof | |
| KR102409595B1 (ko) | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 | |
| US8729130B2 (en) | Methods of using novel solid forms of tacedinaline | |
| EP3689861A1 (en) | Optically active pyrrolidine compound and method for producing same | |
| WO2012003413A1 (en) | Novel solid forms of tacedinaline | |
| CN102060875A (zh) | 新型喹唑啉衍生物、制备方法和用途 | |
| CN103554091B (zh) | 喹唑啉衍生物及其制备方法和用途 | |
| HU231012B1 (hu) | Lapatinib sók | |
| HK40014240A (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
| CZ20003687A3 (cs) | Způsoby inhibice MRP1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20111122 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |